Esperion Therapeutics (NASDAQ: ESPR) reported Q4 EPS of ($1.77), $0.50 better than the analyst estimate of ($2.27). Revenue for the quarter came in at $15.4 million versus the consensus estimate of $14.48 million.

2022 Financial Outlook:

Research and Development expenses for the full year 2022 are expected to be $100 million to $110 million. Selling, General and Administrative expenses for the full year 2022 are expected to be $120 million to $130 million.

Esperion expects full-year 2022 operating expenses to be approximately $220 million to $240 million, inclusive of $25 million of non-cash, stock-based compensation expense.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.